Cargando…
Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home
AIMS: To assess the performance and safety of an integrated bihormonal artificial pancreas system consisting of one wearable device and two wireless glucose sensor transmitters during short‐term daily use at home. METHODS: Adult patients with type 1 diabetes using an insulin pump were invited to enr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111773/ https://www.ncbi.nlm.nih.gov/pubmed/26996542 http://dx.doi.org/10.1111/dom.12663 |
_version_ | 1782467908987781120 |
---|---|
author | Blauw, H. van Bon, A. C. Koops, R. DeVries, J. H. |
author_facet | Blauw, H. van Bon, A. C. Koops, R. DeVries, J. H. |
author_sort | Blauw, H. |
collection | PubMed |
description | AIMS: To assess the performance and safety of an integrated bihormonal artificial pancreas system consisting of one wearable device and two wireless glucose sensor transmitters during short‐term daily use at home. METHODS: Adult patients with type 1 diabetes using an insulin pump were invited to enrol in this randomized crossover study. Treatment with the artificial pancreas started with a day and night in the clinical research centre, followed by 3 days at home. The control period consisted of 4 days of insulin pump therapy at home with blinded continuous glucose monitoring for data collection. Days 2–4 were predefined as the analysis period, with median glucose as the primary outcome. RESULTS: A total of 10 patients completed the study. The median [interquartile range (IQR)] glucose level was similar for the two treatments [7.3 (7.0–7.6) mmol/l for the artificial pancreas vs. 7.7 (7.0–9.0) mmol/l for the control; p = 0.123]. The median (IQR) percentage of time spent in euglycaemia (3.9–10 mmol/l) was longer during use of the artificial pancreas [84.7 (82.2–87.8)% for the artificial pancreas vs. 68.5 (57.9–83.6)% for the control; p = 0.007]. Time in hypoglycaemia was 1.3 (0.2–3.2)% for the artificial pancreas and 2.4 (0.4–10.3)% for the control treatment (p = 0.139). Separate analysis of daytime and night‐time showed that the improvements were mainly achieved during the night. CONCLUSIONS: The results of this pilot study suggest that our integrated artificial pancreas provides better glucose control than insulin pump therapy in patients with type 1 diabetes at home and that the treatment is safe. |
format | Online Article Text |
id | pubmed-5111773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51117732016-11-16 Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home Blauw, H. van Bon, A. C. Koops, R. DeVries, J. H. Diabetes Obes Metab Original Articles AIMS: To assess the performance and safety of an integrated bihormonal artificial pancreas system consisting of one wearable device and two wireless glucose sensor transmitters during short‐term daily use at home. METHODS: Adult patients with type 1 diabetes using an insulin pump were invited to enrol in this randomized crossover study. Treatment with the artificial pancreas started with a day and night in the clinical research centre, followed by 3 days at home. The control period consisted of 4 days of insulin pump therapy at home with blinded continuous glucose monitoring for data collection. Days 2–4 were predefined as the analysis period, with median glucose as the primary outcome. RESULTS: A total of 10 patients completed the study. The median [interquartile range (IQR)] glucose level was similar for the two treatments [7.3 (7.0–7.6) mmol/l for the artificial pancreas vs. 7.7 (7.0–9.0) mmol/l for the control; p = 0.123]. The median (IQR) percentage of time spent in euglycaemia (3.9–10 mmol/l) was longer during use of the artificial pancreas [84.7 (82.2–87.8)% for the artificial pancreas vs. 68.5 (57.9–83.6)% for the control; p = 0.007]. Time in hypoglycaemia was 1.3 (0.2–3.2)% for the artificial pancreas and 2.4 (0.4–10.3)% for the control treatment (p = 0.139). Separate analysis of daytime and night‐time showed that the improvements were mainly achieved during the night. CONCLUSIONS: The results of this pilot study suggest that our integrated artificial pancreas provides better glucose control than insulin pump therapy in patients with type 1 diabetes at home and that the treatment is safe. Blackwell Publishing Ltd 2016-04-25 2016-07 /pmc/articles/PMC5111773/ /pubmed/26996542 http://dx.doi.org/10.1111/dom.12663 Text en © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Blauw, H. van Bon, A. C. Koops, R. DeVries, J. H. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title | Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title_full | Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title_fullStr | Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title_full_unstemmed | Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title_short | Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
title_sort | performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111773/ https://www.ncbi.nlm.nih.gov/pubmed/26996542 http://dx.doi.org/10.1111/dom.12663 |
work_keys_str_mv | AT blauwh performanceandsafetyofanintegratedbihormonalartificialpancreasforfullyautomatedglucosecontrolathome AT vanbonac performanceandsafetyofanintegratedbihormonalartificialpancreasforfullyautomatedglucosecontrolathome AT koopsr performanceandsafetyofanintegratedbihormonalartificialpancreasforfullyautomatedglucosecontrolathome AT devriesjh performanceandsafetyofanintegratedbihormonalartificialpancreasforfullyautomatedglucosecontrolathome AT performanceandsafetyofanintegratedbihormonalartificialpancreasforfullyautomatedglucosecontrolathome |